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INTRODUCTION
Allogeneic stem cell transplantation (SCT) cures many
patients with hematologic malignancies, but is limited by sev-
eral important factors. For instance, only approximately one
third of patients who might benefit from allogeneic SCT
have an HLA-identical sibling. Patients without a well-
matched sibling may be eligible for unrelated donor (URD)
SCT from one of more than 7.3 million volunteers listed on
the National Marrow Donor Program (NMDP) and afﬁliated
international registries. Yet NMDP statistics show that fewer
than 80% of Caucasians and only approximately 50% of
African Americans have a suitably matched unrelated donor
[1]. Even in cases in which a matched unrelated donor is
identiﬁed, the mean interval from initiation of a formal search
to transplantation is approximately 4 months [1]. A delay of
this magnitude is not appropriate for many patients with
aggressive disease, and those who relapse, suffer treatment-
related toxicity, or develop other complications while waiting
often cease to be candidates for transplantation. As a result of
these limitations, fewer than 20% of patients referred for a
preliminary search through the NMDP actually proceed to
transplantation [1]. Consequently, many patients without an
HLA-matched sibling must explore alternative treatments.
Successful SCT is also limited by toxicity associated
with graft-versus-host disease (GVHD) and immunosup-
pression. Grades III and IV acute GVHD develop in 18%
to 50% of recipients of HLA-matched bone marrow from
unrelated donors [2-9], and chronic GVHD occurs in 55%
to 75% of these patients [2,10-14]. T-cell depletion of the
graft and younger recipient age lower the risk of GVHD
[2,11,15], whereas increasing HLA disparity is generally
associated with an increased risk of acute GVHD [2,5,10,
14-16]. Marrow sources that limit the development of
GVHD may improve outcomes of donor SCT.
In light of the problems associated with SCT from adult
donors, umbilical cord blood (UCB) is being explored as an
alternative source of hematopoietic stem cells [17-32].
Edward Boyse has been credited for ﬁrst suggesting in 1983
the possibility of transplanting stem cells derived from UCB
[33]. The idea grew from the observation that the number
of granulocyte-macrophage progenitor cells within the
neonatal circulation remains greater than or equal to that in
adult bone marrow for several hours after birth [34-37].
Subsequent experiments demonstrated that near-term and
neonatal murine blood contains adequate numbers of
hematopoietic stem cells and progenitor cells for bone mar-
row reconstitution in lethally irradiated mice [38].
Through the use of UCB for SCT, some of the limita-
tions of SCT from adult donors may be avoided; several
advantages of UCB SCT are listed in Table 1. First, because
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UCB is typically discarded, it exists in almost limitless sup-
ply. Cord blood banks are being established throughout the
world, and their continued expansion will allow extensive
libraries of HLA types to be established from UCB units.
Theoretically, adequate representation of all races and eth-
nicities would be possible. Second, donor attrition resulting
from aging, relocation, and the development of new medical
conditions does not exist. Third, UCB can be collected easily
and safely, without the cost, anxiety, hospitalization, anesthe-
sia, and postoperative pain involved in harvesting bone mar-
row from a donor. Fourth, as part of the banking process,
UCB is routinely typed for HLA antigens and ABO blood
groups as well as tested for infectious agents. Once banked,
therefore, it is available for transplantation almost immedi-
ately (in less than 2 weeks in many cases [39]). Fifth, GVHD
resulting from UCB transplantation may be less frequent and
less severe than that caused by SCT from adult donors [19-
21,40]. If realized, a reduction in GVHD might allow greater
HLA disparity between donor and recipient and consequent
expansion of the pool of potential donors for a given patient.
As noted in Table 1, there are also several potential dis-
advantages of UCB SCT. The available cell dose may be
insufficient for engraftment, especially in larger pediatric
patients and adults. Additional cells from the same donor
are not available in case of graft failure. Furthermore, the
unique immunologic features of UCB that may result in less
GVHD may also limit graft-versus-tumor (GVT) activity,
and it is not possible to obtain donor leukocytes for sec-
ondary infusions. Finally, there are limited data on the long-
term durability of UCB grafts.
ENGRAFTMENT OF UCB
Preclinical Studies
To be a useful stem cell source, UCB must contain cells
capable of sustaining long-term hematopoietic engraftment.
Although there is no deﬁnitive assay for a human long-term
repopulating cell, surrogate assays have revealed unique
characteristics of UCB hematopoietic progenitor cells that
are not found in their adult marrow counterparts (Table 2).
Phenotypic differences include the enrichment of high–
proliferative potential colony-forming cells and long-term
culture-initiating cells within the HLA-DR+ subpopulation
of CD34+ cells in UCB [41,42]. In contrast, in adult marrow
the CD34+/HLA-DR– phenotype denotes the more primi-
tive subpopulation. This difference in phenotype is signiﬁ-
cant for cellular proliferation: cultures of UCB CD34+ cells
yield an increase in cell number every 7 to 10 days that is
several-hundred–fold greater than the increase in cultures of
similar cells from adult marrow [43]. Additionally, UCB
CD34+ cells have enhanced proliferative capacity compared
to adult marrow cells [44]. Although 97% of both DR+ and
DR– subpopulations in UCB are in G0 or G1 initially, both
subsets proliferate rapidly, so that after 36 hours in
cytokine-supplemented liquid suspension culture, only 50%
are in G0 or G1. In adult marrow, 80% of DR+ and 91% of
DR– cells are in G0 or G1 initially, and 80% of both groups
remain so after 36 hours in culture.
CD34+/CD 38– cells from both UCB and adult marrow
constitute a subpopulation of CD34+ cells remarkable for
sustained clonogenicity in extended long-term culture assays
[45,46]. Compared to marrow cells, however, UCB cells
proliferate for even greater periods of time, proliferate more
rapidly on stimulation with cytokines, and generate larger
numbers of progeny cells [46]. Additional studies implicate
longer telomere length as a factor that may contribute to the
enhanced proliferative capacity of UCB progenitor cells
[47]. Thus, in vitro studies clearly demonstrate that as the
result of multiple factors, UCB progenitor cells possess both
a higher proliferative potential and a greater capacity for
self-renewal and long-term culture growth than do pro-
genitor cells from bone marrow.
Clinical Studies
Despite the unique characteristics of UCB progenitor
cells, there has been concern that UCB recipients would
suffer markedly prolonged periods of aplasia prior to
engraftment [22,24,30,40] and, consequently, increased inci-
dence of infectious complications and graft failure. This
concern is based on 2 facts. First, there are roughly one
tenth as many nucleated cells and CD34+ cells in UCB grafts
as in allogeneic marrow grafts [48-50]. Second, in cases of
matched-sibling and URD SCT, there is an association
Table 1. Potential Advantages and Disadvantages of UCB
Advantages Disadvantages
Limitless supply (including adequate representation of all races Insufficient cell dose resulting in delayed engraftment and increased 
and ethnicities) rates of graft failure in larger pediatric patients and adults
No donor attrition (aging, relocation, loss of interest, medical Uncertain GVT activity 
complications, etc.) Uncertain long-term graft durability
Ease and safety of collection with rapid availability Risk of EBV-associated PTLD 
Reduced acute and chronic GVHD Inability to obtain donor leukocytes in case of relapse, PTLD, or
Reduced viral contamination of grafts other complications 
Table 2. Unique Properties of UCB
High proliferative potential in vitro
Enhanced capacity for self-renewal in vitro
Ability of plasma from UCB units to independently facilitate 
proliferation of progenitor cells
Increased concentration of lymphocytes
Smaller percentage of CD8+ T-cells among lymphocytes
Cell surface markers suggestive of T-cell immaturity
Diminished capacity for antigen presentation
Defective generation of cytotoxic effector cells
Unique cytokine profile
Increased telomere length
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between shorter periods of aplasia and higher numbers of
infused donor cells and CD34+ cells [48,49,51].
Several major studies have demonstrated the engraft-
ment potential of UCB (Table 3). Rubinstein et al. reviewed
data from 562 URD UCB transplantations compiled by the
Placental Blood Program at the New York Blood Center
[25]. Neutrophil recovery occurred in 81% of patients by day
42 (median, 28 days) and platelet recovery in 85% by day
180 (median, 90 days). Factors associated with engraftment
included underlying disease, patient age, degree of HLA dis-
parity, the number of leukocytes in the graft, and the trans-
plantation center. Myeloid engraftment failed in 160 patients;
Table 3. Engraftment Data
Cumulative Median
% of Myeloid Neutrophil
Engraftment Engraftment Factors Affecting
Reference N Recipients Donors (>500/mL) Time, d Myeloid Engraftment
[25] 562 Children HLA-matched and mismatched 81 by day 42 28 Nucleated cell dose, HLA 
and adults unrelated donors 91 by day 60 matching, type of disease, 
transplantation center 
[22] 143 Children HLA-matched and mismatched 79 by day 60 30 Nucleated cell dose, HLA matching, 
and adults related and unrelated donors (related) (related and recipient age, recipient weight 
87 by day 60 unrelated) (related)
(unrelated) Nucleated cell dose, recipient 
weight, HLA matching (unrelated)
[19] 257 Children HLA-matched and mismatched 87 25 Nucleated cell dose
and adults unrelated donors
[21] 113 Children HLA-matched sibling donors 89 by day 60 26 Type of disease, recipient sex, ABO 
matching, GVHD prophylaxis, use 
of posttransplantation growth 
factors 
[20] 99 Children HLA-matched and mismatched 80 by day 60 32 Nucleated cell dose 
unrelated donors
[17] 68 Adults HLA-matched and mismatched 90 by day 42 27 Number of nucleated cells before 
unrelated donors cryopreservation
[52] 102 Children HLA-matched and mismatched 88 by day 42 23 CD34 cell dose >1 × 105/kg
and adults unrelated donors
Table 4. Graft-Versus-Host Disease
% Acute 
GVHD %
(Grades III Chronic
Reference N Recipients Donors or IV) GVHD Predictors
[25] 562 Children HLA-matched and mismatched 22 25 Acute: age, location of transplantation
and adults unrelated donors center, HLA mismatching
Chronic: none
[22] 143 Children HLA-matched and mismatched 5 (related) 14 (related) Acute: HLA mismatching (related),
and adults related and unrelated donors 20 (unrelated) 0 (unrelated) cytomegalovirus status (unrelated)
[19] 257 Children HLA-matched and mismatched 12 7 None (trend toward higher incidence
and adults unrelated donors in melphalan-treated patients)
[21] 113 Children HLA-matched sibling donors 2 5 Acute: nonmalignant disease, shorter
interval between diagnosis and trans-
plantation, absence of major ABO
mismatch, use of methotrexate
(MTX) with cyclosporin A (CSA) for 
GVHD prophylaxis
Chronic: age less than 10 y,
nonmalignant disease, use of MTX 
with CSA for GVHD prophylaxis
[20] 99 Children HLA-matched and mismatched 22 12 None reported
unrelated donors
[17] 68 Adults HLA-matched and mismatched 20 38 None reported 
unrelated donors
[52] 102 Children HLA-matched and mismatched 11 9 No association with CD3 dose, or
and adults unrelated donors HLA matching
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102 died prior to achieving an absolute neutrophil count of
500/µL, 13 had autologous reconstitution, 29 received sec-
ond grafts, and 16 experienced disease relapse.
Gluckman et al. have analyzed data compiled by the
Eurocord registry from 143 UCB transplantations from
both related (n = 78) and unrelated (n = 65) donors [22,26].
By day 60, rates of neutrophil engraftment (>500/µL) were
79% to 87%. Day-60 platelet engraftment (platelets
>20,000/µL) occurred in 62% of related donors and 39% of
unrelated donors. For the entire group, myeloid engraft-
ment occurred at a median of 30 days and platelet engraft-
ment at a median of 56 days. Factors associated with
engraftment included the number of infused nucleated cells
per kilogram recipient weight, recipient age, recipient
weight, and the presence of HLA identity. In an updated
analysis of Eurocord data through March 2000, 83% of
138 children who received transplants of UCB from related
donors and 82% of 291 children who received transplants of
UCB from unrelated donors achieved myeloid engraftment
at median times of 26 and 29 days, respectively [18].
Similar data were obtained in an analysis of 257 patients
from the University of Minnesota and Duke University that
revealed an 87% rate of neutrophil engraftment at a median
of 25 days [19]. Platelet recovery occurred in 51% of patients
at a median of 6 months. Recipients of fewer than 1.5 × 107
nucleated cells/kg recipient weight experienced delayed
engraftment and a greater risk of graft failure. A recent
analysis of data from 102 cord blood recipients at the Uni-
versity of Minnesota revealed that a CD34 cell dose of >1.5 ×
105/kg was the most reliable predictor of neutrophil and
platelet recovery (P < .01). Notably, there was not a statisti-
cally significant association between engraftment and the
total number of nucleated cells per kilogram infused [52].
There was, however, a direct correlation between the num-
ber of CD34+ cells and the total number of nucleated cells.
Two studies by Rocha and colleagues have attempted to
compare engraftment after UCB transplantation to engraft-
ment after transplantation from other sources [20,21]. The
ﬁrst study [21] compared 113 children undergoing transplan-
tation with UCB from HLA-identical siblings to 2052 chil-
dren undergoing transplantation with bone marrow from
HLA-identical siblings. Ninety-eight percent of the bone
marrow transplantation (BMT) group and 89% of the UCB
group achieved myeloid engraftment by day 60 (median, 18
and 26 days, respectively). Multivariate analysis yielded a rel-
ative risk of 0.40 for neutrophil recovery in the ﬁrst month
after UCB SCT compared to BMT. The second study retro-
spectively compared 541 children with acute leukemia
undergoing transplantation with URD stem cells from UCB
(n = 99), T-cell–depleted marrow (n = 180), or unmanipu-
lated marrow (n = 262) [20]; donors had variable degrees of
HLA matching. By day 60, neutrophil recovery had occurred
in 96% of the unmanipulated marrow recipients and in 90%
of the T-cell–depleted marrow recipients but in only 80% of
the UCB recipients (P < .001). Median times to recovery
were 18, 16, and 32 days, respectively. Again, cord blood
engraftment was linked to nucleated cell dose.
These comparative studies suggest that myeloid engraft-
ment occurs more slowly and less frequently in recipients of
UCB than in recipients of allogeneic marrow and that the
limited cell dose in UCB grafts is a major reason for primary
graft failure and delayed hematopoietic recovery. Studies also
suggest, although results are less certain, that HLA disparity
may also delay donor cell engraftment, perhaps via alloim-
munization [25]. In addition, UCB T-cells may have limited
alloreactivity. Just as T-cell depletion of marrow grafts
increases the risk of graft rejection [53-55], the blunted T-cell
activity of UCB may contribute to the increased incidence
of graft failure. 
Although low in comparison to rates of non– T-
cell–depleted adult bone marrow, engraftment rates of
approximately 80% to 90% after UCB transplantation seem
acceptable, particularly in patients without other reasonable
treatment options. In addition, accumulating data provide
evidence for the long-term durability of donor engraftment.
To date, late graft failure has occurred almost exclusively in
patients who had received ganciclovir for the treatment of
documented cytomegalovirus infection (likely contributing
to secondary graft failure) [40].
Most trials of UCB transplantation have been con-
ducted in predominantly pediatric patient populations.
There has been concern that UCB transplantation in adult
recipients might result in even greater engraftment difﬁcul-
ties due to the smaller numbers of infused cells per kilogram
of recipient weight. However, preliminary analyses of rela-
tively small numbers of patients indicate that UCB contains
sufﬁcient numbers of hematopoietic stem cells for sustained
engraftment in adults weighing more than 40 kg. Time
intervals from transplantation to engraftment as well as rates
of primary graft failure have been similar to those in pedi-
atric UCB recipients. In a recent study of 68 adults with a
median age of 31 years and a median weight of 69 kg, 90%
achieved myeloid engraftment by 42 days after donor cell
infusion [17]. Analysis of 108 adults from the Eurocord reg-
istry revealed an 81% probability of myeloid engraftment by
day 60 (median, 32 days) [18]. As in pediatric patients,
engraftment in adult recipients of UCB appears to be slower
and graft failure more frequent than in recipients of allo-
geneic marrow. Similar to ﬁndings in the pediatric population,
a direct correlation was found between time to engraftment
and the number of cryopreserved nucleated UCB cells. The
optimal dose of nucleated cells in UCB grafts is unknown,
although several studies indicate a clear reduction in time to
engraftment and improved outcomes when recipients are
infused with higher cell doses. Recently recommended cell
doses include 1.5 × 107 and 2.0 × 107 nucleated cells/kg
recipient weight [19,56].
To increase cell doses and improve engraftment, some
investigators are using multiple UCB units for SCT [57,58].
Early data suggest that this approach is feasible, resulting in
frequent engraftment without extensive GVHD. A curious
finding was that only 1 UCB unit appeared to engraft. It
remains to be determined if this approach will speed engraft-
ment and hence improve the safety and efﬁcacy of UCB SCT.
GRAFT-VERSUS-HOST DISEASE
Preclinical Studies
T-cells are the primary mediators of GVHD, and the
number of T-cells is signiﬁcantly lower in a URD UCB graft
(8 × 106 CD3 cells/kg recipient weight) [59] than in an
unmodified marrow allograft (30-40 × 106/kg). However,
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studies suggest that in most cases a T-cell dose of <0.1 ×
106/kg is needed to eliminate the risk of severe acute GVHD
that accompanies unrelated marrow transplantation [60,61].
Therefore, although the T-cell dose is much lower in UCB
than in adult marrow allografts, it is not low enough to be
the sole factor accounting for reduction of GVHD after
UCB transplantation. Rather, other plausible explanations
for a reduction in UCB-induced GVHD incorporate quanti-
tative and qualitative differences between the adult and
neonatal immune systems. For instance, despite an increase
in the concentration of lymphocytes in UCB (ie, 2-3–fold
higher numbers of T-cells/mL), the percentage of CD8+
T-cells is lower [62]. This ﬁnding is signiﬁcant because there
is clinical evidence suggesting that CD8+ T-cells are the pri-
mary mediators of GVHD after allogeneic SCT [63].
Cord blood lymphocytes also possess phenotypic traits
suggestive of T-cell immaturity, including increased coex-
pression of CD45RA on CD4+ cells, decreased expression of
interleukin (IL)-2 receptors on CD3+ T-cells, and decreased
coexpression of HLA-DR on CD3+ T-cells [64]. More than
90% of CD4+ cells coexpress CD45RA and CD38, and
experiments have shown that these cells serve as suppressor
cells with no detectable helper function [65]. UCB T-cells
can proliferate normally when activated but may develop
tolerance after repeated exposure to alloantigens [66]. UCB
cells are also defective in generating cytotoxic effector cells
[66]. Finally, compared to their marrow counterparts, UCB
mononuclear cells elaborate a unique cytokine proﬁle con-
sisting of comparable levels of IL-2, IL-6, and tumor necro-
sis factor α but decreased levels of interferon-γ and IL-10
and a complete lack of IL-4 and IL-5 [66].
Clinical Studies
Experiments showing that UCB T-cells may be less
alloreactive than adult T-cells suggest that UCB transplan-
tation might induce less GVHD than transplantation with
stem cells from other sources. In fact, in both related and
unrelated UCB transplantation, as well as in cases of HLA-
matched and -mismatched grafts, the incidence and severity
of acute and chronic GVHD appears to be less than in con-
ventional hematopoietic SCT (Table 4). Despite HLA
mismatching at greater than or equal to 2 loci in the major-
ity of cases, the combined incidence of grades II through IV
acute GVHD ranged from 35% to 40% in approximately
840 predominantly pediatric patients described in 7 clinical
reports [21-23,25,29,30,32]. These percentages appear
favorable compared to the incidence of acute GVHD in
matched URD transplantation [2,11,12] and partially HLA-
mismatched family-member allogeneic BMT [10]. Although
some studies suggest that UCB SCT results in less GVHD,
no trial results have suggested that UCB SCT increases the
risk of GVHD compared to transplantation of cells from
other sources.
In addition to the unique immunologic characteristics of
UCB, another important factor affecting UCB transplanta-
tion is that UCB recipients tend to be young. However, the
reduction in GVHD observed after UCB transplantation
does not seem to be related simply to the younger age of
UCB recipients [20,21]. According to one study in which
results were controlled for age, the relative risk for acute
GVHD was 0.41 and for chronic GVHD was 0.35 for recipi-
ents of HLA-matched–sibling UCB compared to recipients
of HLA-matched–sibling marrow [21]. This study also
avoided the potentially confounding factor of minor–
histocompatibility-antigen disparity, which is more prevalent
among unrelated donor–recipient pairs than among sibling
pairs. A second study from Rocha et al. provides evidence
that the reduction in GVHD extends to children who receive
mismatched URD UCB [20]. Hazard ratios for acute and
chronic GVHD were 0.50 and 0.24, respectively, in UCB
recipients compared to unrelated, unmanipulated BMT
recipients. Results of a study by Laughlin et al. suggest that
the frequency of GVHD may also be reduced in adults
receiving UCB [17]. Adults receiving matched allogeneic
marrow SCT had an 18% to 50% incidence rate of grade III
or IV acute GVHD [2,10,12-14] compared to an incidence
rate of only 20% in adults in this particular study who
received largely HLA-mismatched UCB, although the con-
clusions may be limited by the relatively small numbers of
patients studied. Notably, chronic GVHD developed in 38%
of adults surviving for more than 100 days after transplanta-
tion; this chronic GVHD rate contrasts with reported rates
of 55% to 75% in adults receiving allogeneic stem cell grafts
[2,12,13], although again, direct comparisons are difﬁcult.
The extent to which HLA disparity between recipient
and donor correlates with the frequency and severity of
GVHD is still unclear. In an analysis of data from 257 UCB
transplantations from Duke and the University of Min-
nesota, no association was identified between acute or
chronic GVHD and the degree of HLA matching [19,17].
Rubinstein’s analysis revealed a correlation between the
severity of acute GVHD and the extent of HLA incompati-
bility [25]; HLA mismatching (0 versus 1 or more mis-
matches) correlated with the frequency of severe acute
GVHD (grades III and IV), and this correlation approached
significance according to multivariate analysis results (P =
.06). Eurocord data also showed an association of HLA mis-
matching and GVHD, but only after related UCB SCT
(relative risk, 7.7; P < .001) [22]. Among unrelated donor–
recipient pairs, there was no correlation between the inci-
dence of acute GVHD and the number of HLA mismatches.
It must also be noted that in addition to GVHD reduction
attributable to UCB because of unique features of the
neonatal immune system, further GVHD reduction may
result from the extensive immunosuppression of condition-
ing regimens designed to ensure donor engraftment.
DISEASE RELAPSE AND GRAFT-VERSUS-LEUKEMIA
ACTIVITY
Because transplanted neonatal T-cells appear to induce
less GVHD than do adult T-cells, there is concern that
GVT activity associated with conventional SCT may be
diminished after UCB grafting, leading to an increased rate
of relapse. This concern is based partly on evidence linking
GVT activity with GVHD. This evidence includes the ﬁnd-
ings that (1) GVHD after allogeneic SCT may be protective
against relapse [67,68]; (2) a ﬂare of acute GVHD or with-
drawal of immunosuppression may induce complete remis-
sion in patients with relapsed leukemia [69-71]; and (3)
compared to recipients of unmanipulated grafts, recipients
of T-cell–depleted grafts have an increased risk of relapse
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[67,72], particularly patients with chronic myelogenous
leukemia (CML). The latter observation demonstrates that
GVT activity, as well as GVHD, is mediated at least in part
by donor T-cells. More direct evidence for T-cell–mediated
GVL activity comes from the use of donor leukocyte infu-
sions (DLI) to treat relapse after allogeneic SCT [73-75].
Furthermore, induction of a direct GVT reaction by DLI
has been used as primary therapy for malignant disease [76].
The success of nonmyeloablative allogeneic SCT further
demonstrates the potential for GVT induction by allogeneic
donor grafts [77-80]. In most cases, GVT and GVHD are
closely associated, and any means of diminishing GVHD
might come at the cost of a reduction in GVT activity.
Available data suggest that UCB SCT may be associated
with GVT activity. In a retrospective analysis comparing
patients treated with BMT to those treated with UCB SCT
from HLA-identical siblings [21], the 3-year probability of
survival was similar, whereas persistent or recurrent disease
accounted for 48% of deaths in the UCB group and 49% in
the bone marrow group. In contrast, an analysis of outcomes
after transplantation from unrelated donors demonstrated
increased early transplantation-related mortality (TRM)
(39% versus 19%) and decreased 2-year survival (35% ver-
sus 49%) in UCB recipients compared to bone marrow
recipients [20]. However, the relapse rates at 2 years were
39% and 38% in recipients of bone marrow and UCB,
respectively. These observations suggest that GVT activity
of UCB is similar to that of conventional bone marrow.
Another indirect observation suggesting the presence of
GVT activity after UCB transplantation is highlighted by a
patient with acute lymphoblastic leukemia who suffered a
relapse after transplantation but reentered complete remis-
sion after withdrawal of immunosuppression [81]. It is also
notable that in one study, only 4 (8%) of 48 patients with
CML suffered relapse after UCB transplantation [25]. In
comparison, relapse rates after syngeneic or T-cell–depleted
matched-sibling transplantation, which results in loss of
GVT activity, may be more than 50% [82,83].
Relapse data must be interpreted with caution, however,
particularly because conditioning and immunosuppressive reg-
imens for recipients of UCB SCT may be more intensive than
regimens used for recipients of unmodiﬁed allogeneic bone
marrow. In addition, patients with acute leukemia and
advanced malignancies may be less likely to beneﬁt from the
GVT effects of transplantation [82,84,85]. Similar rates of
relapse therefore might imply either equivalent GVT activity
or lack of GVT activity in both groups. Furthermore,
although one recent report describes successful
nonmyeloablative-conditioned UCB transplantation in 2
patients [86], another trial of nonmyeloablative allogeneic cell
therapy included 7 recipients of UCB grafts, and none of these
patients developed donor chimerism or an antitumor response
[87]. Although the lack of GVT activity in this setting has
many possible explanations, it creates a need for caution about
the use of UCB as a primary source of immunotherapy.
If UCB were less alloreactive than a conventional bone
marrow graft, an increased risk of relapse and Epstein-Barr
virus (EBV)-associated posttransplantation lymphoprolifera-
tive disorder (PTLD) would be anticipated. Treatment
options for either complication are limited. Although DLI
may be remarkably effective for treating relapse after
matched-sibling [74,75] or URD BMT [88], it is not avail-
able after URD UCB SCT. Development of PTLD after
UCB SCT is also of particular concern. The dose of T-cells
in a UCB graft is typically low, HLA mismatches are fre-
quent, and patients are typically conditioned with very
intensive immunosuppression. Additionally, just as the
unique immunologic properties of UCB T-cells may limit
GVHD, they may also limit EBV reactivity. Data counter-
ing these concerns, however, have shown the cumulative
incidence of PTLD after UCB transplantation to have been
only 2% [89]. Nevertheless, without successful DLI [90,91],
patients with PTLD after allogeneic SCT are unlikely to
survive [92]. Because donor leukocytes are not available
after UCB transplantation from unrelated donors, alterna-
tive strategies for augmenting GVT and antiviral activity
should be considered. Suggested approaches include IL-2
augmentation of natural killer cell–mediated cytotoxicity,
ex vivo expansion and activation of UCB T-cells, and
employment of dendritic cell vaccines designed to stimulate
the immune response against neoplastic cells [93-96].
SURVIVAL AND EVENT-FREE SURVIVAL
Data are inconclusive regarding comparative rates of
overall survival after UCB transplantation and URD BMT
but indicate that causes of death differ in the 2 populations.
The Eurocord study compared pediatric recipients of UCB,
unmanipulated bone marrow, or T-cell–depleted marrow
and accounted for differences in prognostic factors in each
group [20]. Mortality due to early treatment-related toxicity
was signiﬁcantly increased in the UCB cohort, whereas acute
GVHD was more frequent in the group receiving unmanip-
ulated marrow. Recipients of T-cell–depleted marrow were
more likely to die from early disease relapse. After day 100,
there were signiﬁcantly lower rates of chronic GVHD in the
UCB and T-cell–depleted marrow groups and similar rates
of death in the UCB and unmanipulated marrow groups.
Eurocord data suggest that TRM rates after URD UCB
SCT are higher in adults (56% at 180 days) than in children
(32% at 180 days) [56]. These differences are likely due to a
number of variables that affect transplantation-related out-
comes and event-free survival (EFS) in UCB recipients,
including nucleated and CD34+ cell doses, HLA matching,
and younger age and lower weight in children. Recipients
of ≤ 1 × 107 nucleated cells/kg had a TRM of 75%, whereas
patients infused with at least 3 × 107 nucleated cells/kg had
a TRM of only 30% [56]; adults and larger pediatric
patients are more likely to receive lower cell doses from
UCB. The degree of HLA matching also predicted TRM,
which was 29% in recipients of fully matched grafts, 34% in
recipients of 1-antigen mismatched grafts, 45% in recipients
of 2-antigen mismatched grafts, and 50% in recipients of
3 or more–antigen mismatched grafts (P = .02). Other stud-
ies, however, have not found an association between HLA
matching and TRM [17,24].
The indication for transplantation is another important
predictor of survival after UCB SCT [18]. Of 138 children
who received transplants of UCB from related donors, the
probability of survival at 2 years was 46% in recipients with
malignancies, 76% in recipients with aplastic anemia, 79%
in recipients with inborn errors of metabolism, and 100% in
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recipients with hemoglobinopathies [18]. Among 291 chil-
dren who received transplants of UCB from unrelated
donors, 2-year EFS was 36% in recipients with malignan-
cies, 21% in recipients with aplastic anemia, and 51% in
recipients with inborn errors of metabolism [18]. In addi-
tion, patients with advanced disease have had worse out-
comes after UCB transplantation compared to patients with
early-stage disease. Among children with acute leukemia in
ﬁrst or second complete remission, the 2-year EFS was esti-
mated at 49% [23], whereas children with more advanced
stages of disease had a 2-year EFS of only 8% (relative risk,
0.40; 95% conﬁdence interval, 0.24-0.65; P = .0003), largely
due to an increase in 1-year TRM and 2-year relapse rates
[18]. In adults with chronic-phase CML or acute leukemia
who received transplants in ﬁrst or second complete remis-
sion, 1-year survival was 39%, whereas only 17% of those
who received transplants in more advanced stages of disease
were alive after 1 year [18].
EX VIVO EXPANSION OF UCB
In an effort to overcome limitations associated with low
cell doses and delayed engraftment, several groups have
explored ex vivo expansion of UCB [97-102]. Through the
use of cytokine-supplemented culture systems, the number
of committed progenitor cells and CD34+ cells can be
expanded while the self-renewing capacity of the stem cell
component is preserved [97,99]. Laboratory studies docu-
menting the absence of coexpansion of maternal mononu-
clear cells have alleviated fears that ex vivo expansion might
lead to vertical transfer of infectious agents as well as
enhanced GVHD [101]. Although ex vivo expansion may
not increase the overall number of nucleated cells available
for transplantation, engraftment has been prompt in the small
numbers of patients who have received ex vivo–expanded
products [98,102]. In a study of 25 adults and 12 children
with hematological malignancies or breast cancer, Shpall et
al. selected CD34+ cells and expanded ex vivo a portion of
each patient’s cord blood graft [102]. Despite a median infu-
sion of only 0.99 × 107 nucleated cells/kg, myeloid engraft-
ment occurred in all patients who were alive and free of
relapsed disease at day 28 (median time to engraftment,
28 days). There was no signiﬁcant correlation between the
number of nucleated cells/kg infused and time to myeloid
engraftment, but there was an association approaching sta-
tistical significance between time to myeloid engraftment
and the number of CD34+ cells/kg infused. The expansion
resulted in a small increase in the number of CD34+ cells
and a small decrease in the total number of nucleated cells
from the UCB units. It was hypothesized that CD34 selec-
tion and ex vivo expansion might enrich for a highly prolif-
erative population of cells and that the improved quality
rather than quantity of cells is important for rapid and sus-
tained engraftment [102]. Notably, grade III-IV acute
GVHD developed in 40% of patients.
Future clinical trials could assess the contribution of ex
vivo expanded cells to donor engraftment through retroviral
marking experiments. Other issues being explored include
the role of stromal elements and accessory lymphoid popu-
lations, as well as further refinement of cytokine recipes
[103-108]. Whether ex vivo expansion will speed engraft-
ment, enhance or minimize GVHD, or improve outcome
after UCB remains to be determined.
ETHICAL ISSUES
As experience with UCB transplantation increases, a
variety of ethical dilemmas arise. For instance, a potential
conflict of interest exists between allogeneic banking and
autologous storage. Transplantation of autologous UCB
may have a limited role. In particular, it may be used with
technology that allows for genetic modiﬁcation of stem cells
in patients with inborn errors of metabolism. Retroviral vec-
tors may transduce hematopoietic stem cells from UCB
more efﬁciently than those from adult marrow, and autolo-
gous transplantation of genetically modiﬁed UCB has been
employed effectively in the treatment of children with
adenosine deaminase deficiency [109]. Inborn errors of
metabolism such as adenosine deaminase deficiency are
exceedingly rare, however, and autologous banking as a
form of biologic insurance may detract from efforts to build
large banks of cryopreserved UCB from unrelated donors. A
reasonable strategy might encourage autologous UCB stor-
age for neonates with an increased risk of disease that may
be treatable by gene therapy and for those in a family with
increased cancer risk [59]. In the case of future malignancy,
however, autologous transplantation may be a suboptimal
treatment strategy given the uncertainty regarding the
potential for GVT activity. In addition, recent evidence sug-
gests that leukemic cells may be present in the fetal and
neonatal circulation of children diagnosed with leukemia as
late as age 10 years [110,111].
The issue of informed donor consent must also be con-
sidered. If UCB is characterized as discarded tissue, then
speciﬁc informed consent for unrelated transplantation is not
required and UCB may be stored anonymously. A conse-
quence of this approach is an inability to identify the donor
at the time of transplantation, precluding additional donor
testing. On the other hand, if full informed consent from the
parent of the donor is obtained, some have suggested that
the donor could obtain rights to the UCB at age 21 years.
Finally, as demonstrated in a successful yet controversial
example, in vitro fertilization can now be performed in con-
junction with preimplantation genetic diagnosis to preselect
HLA-identical embryos for transplantation of UCB
[112,113]. Despite the potential for application in a variety
of diseases, this approach can involve multiple attempts with
attendant high costs and delays in transplantation therapy,
and the ethical and legal implications demand considerable
discussion and debate [112,114].
CONCLUSIONS
Despite the successes of SCT using bone marrow and
cytokine-mobilized peripheral blood, several major prob-
lems continue to impede progress in the improvement of
hematopoietic cell transplantation. These difﬁculties include
delays in donor stem cell procurement, insufﬁcient numbers
of unrelated donors, and severe treatment-related toxicities
from GVHD, infections, and other complications. UCB,
usually discarded, is a largely untapped resource. Cord
blood cells possess an enhanced capacity for progenitor cell
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proliferation and self-renewal in vitro, and clinical experi-
ence to date indicates that cord blood is a viable alternative
to bone marrow and peripheral blood as a source of stem
cells capable of hematopoietic reconstitution. Cord blood
also possesses immunologic traits that may explain an
observed reduction in the incidence of GVHD after UCB
SCT in some cases. Despite prolonged periods of aplasia,
the apparent reduction in the incidence and severity of
GVHD in turn may underlie comparable rates of survival in
some series comparing UCB to adult-donor sources.
Notably, despite evidence linking GVT effects to GVHD,
UCB transplantation does not seem to be associated with
increased rates of disease relapse.
The available data suggest that nucleated cell dose should
be the primary criterion for donor selection. Accumulation
of additional data to better deﬁne the proper composition of
UCB needed for engraftment in different circumstances, as
well as reﬁnement of techniques for ex vivo progenitor cell
expansion and its clinical application, may further enhance
the utility of UCB SCT. Furthermore, clarification of the
role of major and minor histocompatibility antigens in
determining the incidence of GVHD and other outcomes is
also needed to more precisely identify the pool of candidate
donors for an individual recipient. Additional studies
directly comparing UCB to adult-donor sources of stem
cells in more homogenous populations are forthcoming
[18], and more information is needed regarding the use of
hematopoietic growth factors and multiple UCB units to
speed engraftment. Finally, strategies for augmentation of
potential GVT effects require further investigation.
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